

Use of Opioids From Multiple Providers (UOP)

Description of Measure

The proportion of patients 18 years of age and older, receiving prescription opioids for ≥ 15 days during the measurement period, who received opioids from multiple providers. Three rates are reported:

- **Multiple Prescribers.** The percentage of members receiving prescriptions for opioids from ≥ 4 different prescribers during the measurement period.
- **Multiple Pharmacies.** The percentage of members receiving prescriptions for opioids from ≥ 4 different pharmacies during the measurement period.
- **Multiple Prescribers and Multiple Pharmacies.** The percentage of members receiving prescriptions for opioids from ≥ 4 different prescribers **and** ≥ 4 different pharmacies during the measurement period (i.e., the percentage of persons who are numerator compliant for both the Multiple Prescribers and Multiple Pharmacies rates).

Note: A lower rate indicates better performance for all three rates

Medications

Description	Prescription
Opioids	■ Benzhydrocodone ■ Buprenorphine (transdermal patch and buccal film) ■ Butorphanol ■ Codeine ■ Dihydrocodeine ■ Fentanyl ■ Hydrocodone ■ Hydromorphone ■ Levorphanol ■ Meperidine ■ Methadone ■ Morphine ■ Opium ■ Oxycodone ■ Oxymorphone ■ Pentazocine ■ Tapentadol ■ Tramadol

This measure does not include the following opioid medications:

- Injectables.
- Cough and cold products that contain opioids.
- Single-agent and combination buprenorphine products used as part of medication-assisted treatment of opioid use disorder (buprenorphine sublingual tablets, buprenorphine subcutaneous implant and all buprenorphine/naloxone combination products).
- Ionsys® (fentanyl transdermal patch).
- Methadone for the treatment of opioid use disorder.



Arkansas
BlueCross BlueShield
An Independent Licensee of the Blue Cross and Blue Shield Association

Exclusions

Exclusions	■ Members who elect or use hospice services ■ Members who died
Time limit	■ Any time during MY

Strategies for Success

- Educate members on opioid safety, risks associated with the use of multiple opioids from different providers, and about use of Naloxone (Narcan).
- Educate patients on the importance of utilizing a singular pharmacy to fill all their prescriptions.
- Coordinate care with all providers responsible for the care/management of the member.
- Schedule follow up appointment(s) to reassess and adjust any medication regimen.
- Utilize non-narcotic and non-pharmacologic measures to control pain as part of a comprehensive pain management plan.

Resources

- I. National Committee for Quality Assurance, HEDIS® Measurement Year 2026 Volume 2 Technical Specifications for Health Plan



Arkansas Blue Cross and Blue Shield is an Independent Licensee of the Blue Cross and Blue Shield Association.
© 2023 Arkansas Blue Cross and Blue Shield. All rights reserved.